Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Minimal Change Disease Clear all

Conditions: Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions: Transcutaneous auricular vagus nerve stimulation, Sham device; Device
Lead sponsor: Northwell Health; Other
Eligibility: 3 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: New Hyde Park, New York • Philadelphia, Pennsylvania

Conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
Interventions: Biospecimen collection, Data collection; Other
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy Volunteers
Interventions: Secretin; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 15 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions: adalimumab; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 6 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Ann Arbor, Michigan • New York, New York • Charlotte, North Carolina + 1 more

Conditions: Colon Adenocarcinoma, Colorectal Cancer
Interventions: TAS-102, Irinotecan, Standard Treatment, Signatera MRD ctDNA Assay; Drug · Combination Product · Diagnostic Test
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Orange, California

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy; Radiation · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Idiopathic Nephrotic Syndrome
Interventions: Standard of Care, UrApp; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia • Minneapolis, Minnesota • Portland, Oregon

Conditions: Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid, Urologic Diseases, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases, Glomerulonephritis, Nephritis, Nephrosis
Interventions: GFB-887, Placebo; Drug
Lead sponsor: Goldfinch Bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 74
States / cities: Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 66 more

Conditions: Glomerular Disease
Interventions: Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks; Dietary Supplement
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 30 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Wilmington, Delaware • Baltimore, Maryland • New Hyde Park, New York + 1 more

Conditions: Gastroesophageal Reflux
Interventions: Pantoprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 51
States / cities: Alabaster, Alabama • Huntsville, Alabama • Mesa, Arizona + 43 more

Conditions: Growth Hormone Disorder, Adult Growth Hormone Deficiency
Interventions: No treatment given; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 23 Years to 79 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Interventions: Daratumumab, Donor Lymphocyte Infusion, Laboratory Biomarker Analysis; Biological · Procedure · Other
Lead sponsor: Sumithira Vasu; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Interventions: Kidney Biopsy; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: Up to 80 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2030
U.S. locations: 39
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more

Conditions: IgA Nephropathy (IgAN), IgA Vasculitis, Idiopathic Immune Complex Glomerulonephritis, C3 Glomerulopathy, Membranous Nephropathy, Focal and Segmental Glomerulosclerosis, Minimal Change Disease, Anti-Neutrophilic Cytoplasmic Antibody-GN (ANCA), Lupus Nephritis (LN), Alport Syndrome, Infection-related or Post-infectious Glomerulonephritis, Idiopathic Nephrotic Syndrome (INS)
Interventions: Not listed
Lead sponsor: Pediatric Nephrology Research Consortium; Other
Eligibility: Up to 18 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Boston, Massachusetts • Cincinnati, Ohio

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Balance Training, Breathing and Stretching Exercises; Other
Lead sponsor: Texas Woman's University; Other
Eligibility: 60 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Houston, Texas • Sugar Land, Texas • Webster, Texas

Conditions: Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy, Minimal Change Disease, Minimal Change Nephrotic Syndrome, IgM Nephropathy, Nephrotic Syndrome, Glomerular Disease, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome in Children, Nephrotic Syndrome With Edema (Diagnosis), FSGS
Interventions: Interview; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 2 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia, Late Relapse of Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia, Adult Acute Lymphoblastic Leukemia, Interleukin-3 Receptor Subunit Alpha Positive, Minimal Residual Disease, Refractory Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: cyclophosphamide, Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes, laboratory biomarker analysis, Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes, Fludarabine Phosphate; Drug · Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 12 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
Interventions: WAL0921, Placebo; Drug
Lead sponsor: Walden Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more

Conditions: Idiopathic Nephrotic Syndrome, Frequently Relapsing Nephrotic Syndrome
Interventions: Transcutaneous Auricular Vagus Nerve (taVNS) stimulation; Device
Lead sponsor: Northwell Health; Other
Eligibility: 2 Years to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions: trascutaneous auricular vagus nerve stimulation, Sham device; Device
Lead sponsor: Northwell Health; Other
Eligibility: 3 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: New Hyde Park, New York • Philadelphia, Pennsylvania

Conditions: Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome, Membranous Nephropathy, FSGS, MCD, MCD - Minimal Change Disease, Alport Syndrome
Interventions: Communication; Other
Lead sponsor: University of Michigan; Other
Eligibility: 1 Year to 80 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 16
States / cities: Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 11 more

Conditions: Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
Interventions: Serum and renal tissue analysis; Other
Lead sponsor: Meyer Children's Hospital IRCCS; Other
Eligibility: 0 Years to 99 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Multiple Myeloma, Amyloidosis
Interventions: DaraVRD/DaraVCD; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma, Hematologic Neoplasms
Interventions: BPX-501, Rimiducid; Biological · Drug
Lead sponsor: Bellicum Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2033
U.S. locations: 5
States / cities: Atlanta, Georgia • Westwood, Kansas • Buffalo, New York + 2 more

Search by objective public record fields.

taVNS for FRNS in Children

Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)

A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

Vitamin D Supplementation in Glomerular Disease

Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)

Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)

Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

Nephrotic Syndrome Study Network

Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort Study

The Prescriptive Validity of a Novel Fall Risk Clinical Prediction Rule for People With COPD

Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Effect of Daily Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome

A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)

NEPTUNE Match Study

SLIT ABS: Study on Patients With Autoimmune Podocytopathy

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant